Mindstate Design Labs: Pioneering Psychedelic Drug Development
Revolutionizing Mental Health Therapeutics
Mindstate Design Labs is at the forefront of psychedelic drug development, focusing on designing altered states of consciousness to enhance mental health treatments. Our innovative approach aims to map the biological basis of psychedelic experiences, enabling precision design of modified conscious states.
Key Features
- Osmanthus Platform: A target discovery and phenotypic screening platform combining natural history, natural language processing, and biochemical data.
- Pipeline of Primers & Probes: Utilizing a combination of psychedelic "primer" compounds and non-psychedelic "probe" compounds to modulate altered states of consciousness.
- Precision Design: Mapping the varieties of psychedelic experiences to create tailored mental health therapeutics.
Use Cases
- Mental Health Treatment: Developing therapies for conditions such as depression, anxiety, and PTSD.
- Research and Development: Providing a platform for further scientific exploration into the effects and applications of psychedelics.
- Clinical Trials: Conducting rigorous testing to ensure the safety and efficacy of new psychedelic compounds.
Pricing
Our pricing model is tailored to the needs of our clients, ranging from research institutions to pharmaceutical companies. Contact us for detailed pricing information and customized solutions.
Teams
Our team comprises experts in biotechnology, pharmacology, neuroscience, and data science, including:
- Dillan DiNardo, Co-Founder & CEO: Biotechnology investor and operator with extensive venture capital experience.
- Thomas Ray, PhD, Scientific Co-Founder: Evolutionary biologist and pioneer in artificial life and psychedelic research.
- Paul Wren, PhD, Chief Scientific Officer: Translational pharmacologist with decades of experience in neuroscience R&D.
- David Hough, MD, Head of Clinical Development: Psychiatrist and clinical development executive with a track record of FDA-approved therapeutics.
- Tilmann Brotz, PhD, Head of Preclinical Development: Neuroscientist and drug development expert.
- Jessica Smith Beaver, PhD, MLS, Head of Regulatory Affairs: Regulatory leader with a strong background in healthcare compliance and risk management.
- Jianhong Wang, PhD, Head of DPMK: Expert in clinical pharmacology and drug metabolism.
- Tom Richardson, PhD, Head of Medicinal Chemistry: Medicinal chemist with extensive experience in drug discovery.
- Jasminder Soto, Head of Clinical Operations: Clinical research expert with a focus on global clinical trials.
- Bruce Rehlaender, PhD, Head of Drug Product & Formulation: Specialist in formulation development and drug delivery technologies.
- Tegan Johnson, Director of Operations: Engineering physicist turned medtech project manager.
- Drew Thieme, PhD, Cheminformatician: Expert in data science and computational chemistry.
- Lex Levkovskyy, Data Scientist: Software development and machine learning engineer.
- Ahnjili ZhuParris, Data Scientist: Cognitive neuroscientist and machine learning expert.
- Bethany Leins, PMP, Project Manager, Drug Development: Biopharmaceutical industry veteran.
- Josie Kins, Project Manager, Platform Development: Leader in the psychonautic community and founder of PsychonautWiki.org.
Our advisors include renowned scientists and industry leaders who guide our research and development efforts.
Join us in revolutionizing mental health therapeutics through the precision design of altered states of consciousness.
